Lck BP-1 Activators
Lck BP-1 Activators encompass a diverse array of chemical compounds that indirectly augment the functional activity of Lck BP-1 through various signaling pathways, thus enhancing its role in cellular processes. Forskolin, by elevating intracellular cAMP levels, indirectly boosts Lck BP-1's activity. This occurs through the activation of protein kinase A (PKA), which phosphorylates proteins in pathways where Lck BP-1 is active, leading to an enhancement of its function. Similarly, the PKC activator Phorbol 12-myristate 13-acetate (PMA) and the kinase inhibitor Epigallocatechin gallate (EGCG) play pivotal roles in modifying signaling cascades that converge on Lck BP-1. PMA activates PKC, which then influences downstream pathways involving Lck BP-1, while EGCG modulates various kinases, indirectly promoting Lck BP-1 activity. Staurosporine, despite its broad-spectrum kinase inhibition profile, can selectively enhance Lck BP-1 activity by suppressing kinases that negatively regulate Lck BP-1-associated pathways. In a similar vein, PI3K inhibitors like LY294002 and Wortmannin adjust cellular signaling balance, indirectly upregulating pathways where Lck BP-1 is active. U0126 and SB203580, targeting MEK1/2 and p38 MAPK respectively, shift signaling dynamics in favor of pathways engaging Lck BP-1, thereby enhancing its activity.
Further contributing to the regulation of Lck BP-1 are compounds that affect lipid and calcium signaling. Sphingosine-1-phosphate, through its role in lipid signaling, modifies cellular processes that are integral to Lck BP-1's function, thus enhancing its activity. Genistein, by inhibiting tyrosine kinases, reduces competitive signaling and shifts the balance towards pathways in which Lck BP-1 is involved. Thapsigargin and A23187 (Calcimycin), both influencing intracellular calcium levels, activate calcium-dependent signaling pathways, thereby potentiating Lck BP-1's role in these pathways. Thapsigargin achieves this by increasing calcium levels, which then triggers pathways linked to Lck BP-1, while A23187 acts as an ionophore, leading to a similar enhancement of Lck BP-1's activity.
SEE ALSO...
Items 1 to 10 of 11 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Forskolin | 66575-29-9 | sc-3562 sc-3562A sc-3562B sc-3562C sc-3562D | 5 mg 50 mg 1 g 2 g 5 g | $76.00 $150.00 $725.00 $1385.00 $2050.00 | 73 | |
Forskolin, by increasing intracellular cAMP levels, indirectly enhances the functional activity of Lck BP-1. The elevation of cAMP activates protein kinase A (PKA), which can phosphorylate and modify the activity of proteins involved in signaling pathways linked to Lck BP-1, leading to its enhanced functional activity. | ||||||
PMA | 16561-29-8 | sc-3576 sc-3576A sc-3576B sc-3576C sc-3576D | 1 mg 5 mg 10 mg 25 mg 100 mg | $40.00 $129.00 $210.00 $490.00 $929.00 | 119 | |
PMA acts as a PKC activator. PKC, upon activation, plays a crucial role in the modulation of signaling pathways that are directly related to Lck BP-1. Activation of PKC leads to downstream signaling events that can upregulate the activity of Lck BP-1. | ||||||
Staurosporine | 62996-74-1 | sc-3510 sc-3510A sc-3510B | 100 µg 1 mg 5 mg | $82.00 $150.00 $388.00 | 113 | |
Staurosporine, a broad-spectrum protein kinase inhibitor, can selectively enhance the activity of Lck BP-1 by inhibiting kinases that negatively regulate pathways associated with Lck BP-1. This leads to a relative increase in Lck BP-1 signaling. | ||||||
LY 294002 | 154447-36-6 | sc-201426 sc-201426A | 5 mg 25 mg | $121.00 $392.00 | 148 | |
LY294002 is a PI3K inhibitor that, by inhibiting PI3K, alters downstream signaling pathways. This inhibition can result in the relative upregulation of alternative pathways, including those in which Lck BP-1 is involved, thus enhancing its activity. | ||||||
D-erythro-Sphingosine-1-phosphate | 26993-30-6 | sc-201383 sc-201383D sc-201383A sc-201383B sc-201383C | 1 mg 2 mg 5 mg 10 mg 25 mg | $162.00 $316.00 $559.00 $889.00 $1693.00 | 7 | |
This compound modulates lipid signaling pathways. By influencing these pathways, sphingosine-1-phosphate can enhance the functional activity of Lck BP-1 through the modulation of cellular processes that Lck BP-1 is directly involved in. | ||||||
Genistein | 446-72-0 | sc-3515 sc-3515A sc-3515B sc-3515C sc-3515D sc-3515E sc-3515F | 100 mg 500 mg 1 g 5 g 10 g 25 g 100 g | $26.00 $92.00 $120.00 $310.00 $500.00 $908.00 $1821.00 | 46 | |
Genistein, a tyrosine kinase inhibitor, may enhance Lck BP-1 activity by reducing competition from tyrosine kinase signaling, thus favoring signaling pathways in which Lck BP-1 is directly involved. | ||||||
Thapsigargin | 67526-95-8 | sc-24017 sc-24017A | 1 mg 5 mg | $94.00 $349.00 | 114 | |
Thapsigargin increases intracellular calcium levels, thereby activating calcium-dependent signaling pathways. This increase can potentiate the signaling pathways that involve Lck BP-1, leading to its enhanced functional activity. | ||||||
(−)-Epigallocatechin Gallate | 989-51-5 | sc-200802 sc-200802A sc-200802B sc-200802C sc-200802D sc-200802E | 10 mg 50 mg 100 mg 500 mg 1 g 10 g | $42.00 $72.00 $124.00 $238.00 $520.00 $1234.00 | 11 | |
EGCG, a kinase inhibitor, influences various signaling pathways, potentially leading to the activation of pathways in which Lck BP-1 is involved, thus enhancing its functional activity. | ||||||
A23187 | 52665-69-7 | sc-3591 sc-3591B sc-3591A sc-3591C | 1 mg 5 mg 10 mg 25 mg | $54.00 $128.00 $199.00 $311.00 | 23 | |
A23187 elevates intracellular calcium levels, activating calcium-dependent signaling pathways. This can enhance Lck BP-1 activity by promoting pathways that are calcium-dependent and in which Lck BP-1 plays a role. | ||||||
SB 203580 | 152121-47-6 | sc-3533 sc-3533A | 1 mg 5 mg | $88.00 $342.00 | 284 | |
SB203580 inhibits p38 MAPK, leading to the modulation of cellular signaling pathways. This inhibition can indirectly enhance the activity of Lck BP-1 by shifting signaling towards pathways where Lck BP-1 is more active. | ||||||